NICE Single Technology Appraisal Guidance No 177 – Alitretinoin
for the treatment of severe chronic hand eczema
NICE Single Technology Appraisal Guidance No
177 – Alitretinoin for the
treatment of severe chronic hand eczema
The web reference for the appraisal and other related
documents is: www.nice.org.uk/TA177
NHSScotland should note
that:
1. Recommendations of NICE Single Technology Appraisals (STAs)
have no status in NHS Scotland
2. NHS Boards should continue to adhere to the SMC advice.
3. The Scottish Medicines Consortium (SMC) published a Statement
of Advice on this medication for this indication in March 2009.
This stated that:
Alitretinoin (ToctinoÒ) is accepted for
use within NHS Scotland in adults who have severe chronic hand
eczema that is unresponsive to treatment with potent topical
corticosteroids. Evidence is limited to a randomised
placebo-controlled study where alitretinoin was superior to placebo
in terms of the primary endpoint, Physician Global Assessment of
response.
It is recommended that alitretinoin is dispensed by a
hospital-based pharmacy.
Access the advice of the Scottish Medicines
Consortium:
http://www.scottishmedicines.org.uk/smc/6446.html
If you need further assistance, please contact Eleanor Brownlee
in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net)
Published Date: 26 August 2009
